All News
Filter News
Found 23,144 articles
-
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
4/3/2024
Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.
-
Merck’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
4/3/2024
Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, has secured a $14 million investment led by M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and supported by existing investors, bringing the total funding to $60 million.
-
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
4/3/2024
Bristol Myers Squibb announced that the European Commission has expanded approval of Reblozyl® to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes.
-
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
4/3/2024
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer.
-
Prilenia Names Jina Swartz, M.D. Ph.D., as Chief Medical Officer
4/3/2024
Prilenia Therapeutics B.V. today announced the appointment of Dr. Jina Swartz, M.D. Ph.D., as its first Chief Medical Officer (CMO).
-
Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic
4/3/2024
Nimble Therapeutics today announced the opening of a second R&D site in Philadelphia, PA.
-
In Vitro Fertilization Market Experiencing Rapid Expansion
4/2/2024
According to Vision Research Reports, the global in vitro fertilization market size was estimated at USD 25.34 billion in 2023 and it is projected to hit around USD 43.57 billion by 2033
-
Single-cell Analysis Market Poised for Substantial Growth 18.33%
4/2/2024
The single-cell analysis market size was estimated at USD 4.64 billion in 2023 and it is increasing up to USD 24.97 billion by 2033
-
Indegene Hosts Inaugural Strategic Advisory Board Meeting Chaired By Renowned Global Biopharma Leader Jill DeSimone
4/2/2024
Indegene, a digital-first, life sciences commercialization company, hosted its first Strategic Advisory Board meeting recently in New Jersey, chaired by Jill DeSimone, a well-known biopharma leader, with over four decades of global experience.
-
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
4/2/2024
Vaccinex, Inc. today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.
-
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
4/2/2024
AstraZeneca and Daiichi Sankyo’s Biologics License Application for datopotamab deruxtecan has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor -positive, HER2-negative breast cancer who have received prior systemic therapy for unresectable or metastatic disease.
-
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
4/2/2024
Jaguar Health, Inc. today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International.
-
Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board
4/2/2024
Oncoinvent AS announced the appointment of newly elected members of its Board of Directors and the formation of a Scientific and Clinical Advisory Board under the leadership of founding scientists Roy Larsen and Øyvind Bruland, previous board members and leading experts in oncology and pharmaceutical development.
-
BioInvent Announces a New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1910, the Company’s Second Anti-TNFR2 Antibody in Combination with KEYTRUDA(R) (Pembrolizumab)
4/2/2024
BioInvent International AB today announces a clinical trial collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, for a Phase 1/2a study of its monoclonal antibody BI-1910 in combination with KEYTRUDA® (pembrolizumab).
-
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
4/2/2024
Daiichi Sankyo and AstraZeneca’s Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer who have received prior systemic therapy for unresectable or metastatic disease.
-
Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
4/1/2024
Turbine and Harmonic Discovery have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine's Simulated Cell™ platform.
-
Microbiology Testing Market Experiencing Rapid Growth
4/1/2024
The global microbiology testing market size was valued at USD 5.33 billion in 2023 and it is expected to surpass around USD 12.72 billion by 2033 with a CAGR of 9.12% from 2024 to 2033 due to the increasing demand for genetic testing services.
-
Automated Cell Counter Market Experiencing Rapid Expansion
4/1/2024
The global automated cell counter market size was valued at USD 6.48 billion in 2023 and it is projected to surpass around USD 11.20 billion by 2033 with a CAGR of 5.62% from 2024 to 2033.
-
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
4/1/2024
Merck, known as MSD outside of the United States and Canada, will hold its first-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 25.
-
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
3/29/2024
Adlai Nortye Ltd. announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.